ArticleTranslational andrology and urology2025
The disease burden of kidney cancer in Asian countries and regions from 1990 to 2021: a study based on the Global Burden of Disease database.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are huge differences in the disease burden of kidney cancer (KC) between countries and regions in Asia. Therefore, we conducted this study to investigate the KC burden and attributable risk factors in Asia. Methods: We obtained data on the incidence, prevalence, mortality, disability adjusted life years, sociodemographic index (SDI), and attributable risk factors of KC in Asian countries and regions from 1990 to 2021 in the Global Burden of Disease database. Joinpoint regression was used to analyze the overall trend of the change in KC burden in Asia. The health inequalities of KC in Asia were evaluated. The correlation between SDI and KC burden was assessed. Autoregressive integrated moving average was used to predict the KC burden in the next 15 years. The age-period-cohort model evaluated the relative risk (RR) of the KC burden in different dimensions. In addition, frontier analyses were performed in this study. Finally, comprehensive analyses of the attributable risk factors of KC were performed. Results: The KC burden in Asia showed a significant upward trend from 1990 to 2021. The KC burden was mainly concentrated in relatively wealthy countries and regions (high SDI). In the next 15 years, the KC burden would rise further. The RR of KC generally increased with age and period, and decreased with birth cohorts. The most concerning risk factor for KC was high body mass index (HBMI), and the KC burden attributed to HBMI also indicated a significant upward trend and was positively correlated with SDI. Conclusions: The KC burden in Asian countries and regions is still rising. Therefore, targeted medical interventions are needed to improve early diagnosis and treatment of KC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.